Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Trial Profile

Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Dec 2013

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to completed.
    • 06 Jan 2013 Planned end date (1 Jan 2014) added as reported by Oregon Health and Science University Institutional Review Board.
    • 06 Jan 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board: IRB00008812).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top